Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | C1R | P00736 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691324 | 0.90 | TP53 (0.47) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL2438784 | 0.88 | HDAC6 (0.44) | NPC1RAB9APKMSMN1; SMN2MAPT | |
| SCHEMBL2432634 | 0.88 | GAA (0.45) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL2429466 | 0.84 | ITGA4 (0.56) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL14500941 | 0.83 | NPC1 (0.48) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL7702288 | 0.81 | ITGB1 (0.59) | RAB9AITGA4ITGB1HPGD | |
| SCHEMBL5690943 | 0.81 | ITGB1 (0.59) | RAB9AITGA4ITGB1HPGD | |
| SCHEMBL2432748 | 0.81 | NPC1 (0.60) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL14592361 | 0.81 | NPC1 (0.46) | TP53NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL5363629 | 0.79 | TP53 (0.38) | TP53NPC1RAB9AITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392306-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | AVENTIS PHARMA LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-7211586-B2 | Substituted tetrahydroisoquinolines | AVENTIS PHARMA LIMITED (GB) | 2007-05-01 | — | — | US | disclosed |
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1153017-B1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1183254-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | AVENTIS PHARMA LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040122047-A1 | Substituted tetrahydroisoquinolines | AVENTIS PHARMA LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| US-6706738-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1392306-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Aventis Pharma Limited (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-6593354-B2 | Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 | AVENTIS PHARMA LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| WO-2002098426-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | AVENTIS PHARMA LIMTIED (GB) | 2002-12-12 | — | — | WO | disclosed |
| US-20020173506-A1 | Substituted bicyclic heteroaryl compounds and their use as integrin antagonists | AVENTIS PHARMA LIMITED (GB) | 2002-11-21 | — | — | US | disclosed |
| US-20020137782-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| EP-1183254-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | Aventis Pharma Limited (GB) | 2002-03-06 | — | — | EP | disclosed |
| EP-1153017-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | Aventis Pharma Limited (GB) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000061580-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS | AVENTIS PHARMA LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000049005-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LIMITED (GB) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173506-A1 | Substituted bicyclic heteroaryl compounds and their use as integrin antagonists | VCAM1, ITGA4, ITGA1 | TP53 3768/4885NPC1 1419/4885RAB9A 3747/4885 |
| US-20020137782-A1 | Substituted bicyclic compounds | ITGA1, VCAM1, ITGB1 | TP53 2919/4885NPC1 1396/4885RAB9A 3283/4885 |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | TP53 3945/4885NPC1 1314/4885RAB9A 2426/4885 |
| US-20040122047-A1 | Substituted tetrahydroisoquinolines | VCAM1, ITGA1, ITGB3 | TP53 4280/4885NPC1 1798/4885RAB9A 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.